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Abstract
Background: Haemostasis in liver surgery remains a challenge despite improved resection techniques. Oozing
from blood vessels too small to be ligated necessitate a treatment with haemostats in order to prevent
complications attributed to bleeding. There is good evidence from randomised trials for the efficacy of fibrin
sealants, on their own or in combination with a carrier material. A new haemostatic device is Sangustop®. It is a
collagen based material without any coagulation factors. Pre-clinical data for Sangustop® showed superior
haemostatic effect. This present study aims to show that in the clinical situation Sangustop® is not inferior to a
carrier-bound fibrin sealant (Tachosil®) as a haemostatic treatment in hepatic resection.
Methods/Design: This is a multi-centre, patient-blinded, intra-operatively randomised controlled trial. A total of 126
patients planned for an elective liver resection will be enrolled in eight surgical centres. The primary objective of
this study is to show the non-inferiority of Sangustop® versus a carrier-bound fibrin sealant (Tachosil®) in achieving
haemostasis after hepatic resection. The surgical intervention is standardised with regard to devices and techniques
used for resection and primary haemostasis. Patients will be followed-up for three months for complications and
adverse events.
Discussion: This randomised controlled trial (ESSCALIVER) aims to compare the new collagen haemostat
Sangustop® with a carrier-bound fibrin sealant which can be seen as a “gold standard” in hepatic and other visceral
organ surgery. If non-inferiority is shown other criteria than the haemostatic efficacy (e.g. costs, adverse events rate)
may be considered for the choice of the most appropriate treatment.
Trial Registration: NCT00918619.
Background
All surgical procedures inevitably lead to bleeding. Hae-
mostasis - the control of bleeding - aims at reducing the
amount of blood loss and the need for transfusion as
well as preventing re-bleeding, haematoma formation
with subsequent morbidities, and the need for interven-
tion or repeat surgery. During liver resection the control
of bleeding is a major concern. The liver is predisposed
to a diffuse bleeding because of its extreme vascularity,
particularly because of the hepatic sinusoidal structure,
which does not have smooth muscles capable of con-
traction to induce vasoconstriction.
Surgical techniques and devices to facilitate haemosta-
sis have been developed in the last decades and have
minimised operative risks of liver resection. Neverthe-
less, a parenchymal transsection of the liver tissue is
always associated with some degree of bleeding due to
the division of small blood vessels which can not be iso-
lated and ligated.
In order to achieve control over that parenchymatic
diffuse bleeding from the resection surface and to pre-
vent intraperitoneal complications attributed to bleeding
various locally applicable agents (haemostats) are in use.
These haemostats include bone wax, gelatine, collagen,
oxidized regenerated cellulose, fibrin sealant glues, and
synthetic glues [1]. Some evidence from randomized
controlled trials (RCT) exists regarding the use of fibrin
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fleece [2,3].
A composite product with well documented efficacy is
Tachosil® [Nycomed, Linz, Austria]. It consists of a col-
lagen fleece carrying the fibrin glue components human
fibrinogen and human thrombin. It was shown in a
RCT to be superior in obtaining intraoperative haemos-
tasis over argon beamer in liver resection [4]. The time
to haemostasis was significantly reduced. Also in kidney
tumour resection a randomized study showed superior-
ity over standard suturing [5].
A new haemostat product is Sangustop® [Aesculap,
Tuttlingen, Germany]. It is indicated for local haemos-
tasis of capillary bleeding and bleeding of parenchymal
organs. Sangustop® is composed of native absorbable
collagen fibrils without any blood serum products or
any pharmaceutical activity. The felt structure being
rich in surface gives a framework for the adhesion of
blood platelets, thus provides an additional impetus to
clotting. Pre-clinical data showed very good haemo-
static activity, superior to sealant and to cellulose pro-
duct [6].
The aim of this study is to show that the new microfi-
brillar collagen hemostat Sangustop® is not inferior to
the carrier-bound fibrin sealant Tachosil® with regards
to haemostatic efficacy. The efficacy of Tachosil® has
been shown in many clinical studies in various indica-
tions and thus can be seen as a standard treatment
superior to other locally applicable agents [4,5].
Methods/Design
Objectives
This study is designed as a prospective, single blinded,
randomized, 2-arm trial of two haemostatic products.
The primary objective of the study is to show the non-
inferiority of Sangustop® (Treatment Arm 1) versus
Tachosil® (Treatment Arm 2) in achieving haemostasis
after hepatic resection.
Primary endpoint
▪ Haemostasis 3 minutes after application of the hae-
mostatic product.
Secondary endpoints
▪ Haemostasis 5 minutes after application of the hae-
mostat product.
▪ Haemostasis 10 minutes after application of the hae-
mostat product.
▪ Time to haemostasis
▪ Complications and adverse events intra-operatively
during liver resection and during 3 months of follow-up.
Interventions
Surgery
Liver resection (segmental or non-segmental) will be
performed according to accepted surgical standards.
Surgeons must be board certified and must have a mini-
mum experience of 10 liver resections performed.
A standardization of surgical technique will be done
inasmuch as there is a restriction in the methods
allowed for resection and for primary haemostasis.
The following techniques of liver resection are
allowed:
▪ Cavitron Ultrasonic Aspiration (CUSA®)
▪ Hydrojet (pressurized jet of water)
▪ Clamp Crushing
▪ Scissors
▪ Stapler transsection
The following techniques of liver resection are not
permitted:
▪ Argon beamer (Argon-Plasma Coagulation)
▪ Radiofrequency-assisted devices for parenchymal
division (e.g. Habib™-Sealer, TissueLink™)
▪ Ultrasonic dissection (e.g. UltraCision®)
The following methods of primary haemostasis are
allowed:
▪ Vascular clips
▪ Sutures
All other methods of primary haemostasis (e.g. Argon
Laser, bipolar coagulation) are not permitted.
After primary haemostasis has been achieved and with
persistent parenchymal bleeding the patient will be ran-
domized to one of two treatment groups. Either Sangu-
stop® or Tachosil® will be applied to the resection area
according to the respective instructions for use and the
time to haemostasis will be recorded.
Follow-up
After surgery, two follow-up examinations will be per-
formed while the patients are still hospitalised. Patients
are observed for 3 months for documentation of adverse
events. See Table 1 for detailed follow-up.
Study materials
Sangustop® (B. Braun Aesculap, Tuttlingen, Germany) is
a felt-like haemostatic agent, composed of native
absorbable collagen fibrils of bovine origin and contain-
ing riboflavin as a colouring agent.
TachoSil® (Nycomed, Linz, Austria) is a ready-to-use
fixed combination of a patch sponge (equine collagen)
coated with a dry layer of the human coagulation factors
fibrinogen and thrombin.
Both investigational products of this clinical trial are
approved for clinical use (CE-mark and EU Marketing
Authorisation, respectively). They will be used according
to respective instructions for use within their usual
range of indication.
Trial population
Clinical trial participants will be recruited in the clinical
trial centres consecutively from a population of patients
who are planned for an elective liver resection.
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T a b l e2 .O n ep a r to ft h ee l i g i b i l i t yc r i t e r i aa r ec h e c k e d
preoperatively. A second set of criteria must be checked
intra operatively. Patients who do not meet the second
part of the eligibility criteria will neither be randomised
nor treated with an investigational product. Their trial
participation will end by this time. Regular monitoring
visits will be performed and the eligibility of all enrolled
patients will be checked by source data verification.
Resection area will be calculated with the aid of a paper
blot of the resection surface.
Sample size
The sample size was calculated to test for non-inferiority
of Treatment Arm 1 (Sangustop®) versus Treatment Arm
2 (Tachosil®) in terms of haemostasis 3 minutes after
application of the haemostatic product. The proportion
of patients with a complete haemostasis 3 minutes after
application will be assessed. In a previous study [4] the
proportion of patients with complete blood clotting after
3 minutes for Tachosil® was estimated to be 73%.
With 60 subjects in each group, the lower limit of the
observed one-sided 97,5% confidence interval will be
Table 1 Flow-Chart: Overview Clinical Trial Study Activities
Visit 1
Screening
2
Surgery
3
Follow-up
24 hrs after
surgery
4
Follow-up
7 days after
surgery
5
Follow-up
30 after
surgery
6
Follow-up
3 months after
surgery
Informed consent x
Demographics x
Medical history x
Medication history x
Physical examination x
Blood and urine examinations X
1, 4 X
1 X
1
Eligibility Criteria X
2 X
3
Randomisation X
Liver resection (Resection area, weight,
histopathology, prim. haemostasis)
X
Investigational treatment Sangustop®/
Tachosil®
Number of Sangustop® Compresses/Tachosil®
Sponges used
X
Time to haemostasis X
Required blood transfusions X
Central venous pressure X
Adverse events incl. complications X X X X X
1Blood: INR, PTT, Hb, Ht;
21st part;
32nd part,
4Blood or urine: pregnancy test.
Table 2 Eligibility Criteria
Inclusion Criteria Exclusion Criteria
▪ Age: >18 years
▪ Patients with an indication for liver resection
(segmental or non-segmental)
▪ Willing and able to complete the clinical trial
procedures, as described in the protocol
▪ Signed written informed consent to participate in
this clinical trial
Criteria to be checked at screening visit:
▪ Presence or sequelae of coagulation disorder, liver cirrhosis, Klatskin tumour
▪ Concurrent participation in another clinical trial with a medical device or medicinal
product or with interfering endpoints
▪ Concurrent or previous therapy with systemic pharmacologic agents promoting blood
clotting including but not limited to tranexamix acid, activated factor VII, and aprotinine
▪ Known allergy or hypersensitivity to a component of the investigational treatments
Sangustop® or Tachosil®, to riboflavin or to proteins of bovine origin
▪ Pregnancy or breast feeding
▪ Inability to understand the nature and the extent of the trial and the procedures required
Criteria to be checked during surgery:
▪ Resection area estimated by operating surgeon <16 cm
2
▪ Infected wound area
▪ Persistent major bleeding after primary haemostasis
▪ No bleeding after resection
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proportion of Treatment Arm 2, πS,i s0 , 7 3 0a n dt h e
expected proportion of Treatment Arm 1, πT, is 0,880;
results are based on 100 simulations using the New-
combe-Wilson score method to construct the confi-
dence interval [7].
In case of non-inferiority an additional two group
c
2-test with a 0,050 two-sided significance level will
have 83% power to detect the difference between an
Treatment Arm 2 proportion, π1, of 0,730 and an Treat-
ment Arm 1 proportion, π2, of 0,930 (odds ratio of
4,914) when the sample size in each group is 60.
Assuming a drop-out rate of 5% a total number of 126
patients needs to be enrolled. Figure 1 shows a flow dia-
gram of the progress through the trial phases.
Randomisation and blinding
Randomisation is designed in a way that both treatment
arms will have the same number of patients, with a ran-
domisation ratio of 1:1 providing equal probability of
assignment to each of the two treatment arms. Rando-
misation is stratified by clinical trial centre and will be
performed as block randomization. A separate randomi-
sation list will be created for each clinical trial centre
using the Software RandList of the DatInf GmbH,
Tübingen, Germany.
Only if a patient fulfils all eligibility criteria he/she will
be randomised to an investigational treatment. This will
take place during surgery, since part of the exclusion cri-
teria can only be checked during the operation (liver
resection). For allocation of the randomisation numbers
to eligible trial participants each clinical trial centre will
be provided with a set of identical look, opaque and well
sealed envelopes. If a patient turns out to be eligible the
investigator opens the next envelope in sequence. Inside
he will find the randomisation number and the allocated
investigational treatment. The sequence of opening the
envelopes will be monitored regularly.
This is a single blinded clinical trial. The clinical trial
patients will not be informed about their assignment to
Figure 1 Flow-Chart acc. to CONSORT.
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operating room immediately before the application of
the product. Thus the investigator does not know which
product will be used during transection, during primary
haemostasis, and when assessing the intra-operative
inclusion criteria. However, the appearance of the pro-
ducts precludes a complete blinding of the investigators.
Statistical analysis
Primary Variable
The proportion of patients with haemostasis 3 minutes
after application of the haemostat product as well as
associated 95% confidence intervals will be reported for
each treatment arm. The study null hypothesis is that
Tachosil® is more effective than Sangustop®. Non-infer-
iority will be demonstrated if the lower limit of the
observed two-sided 95% confidence interval of the
observed difference in proportions of Treatment Arm 1 -
Treatment Arm 2 does not fall below -0.100. The analysis
will be based on the per-protocol population and
repeated for the intent-to-treat population. The intent-
to-treat population consists of all consenting patients
randomized into the study. The safety population com-
prises all treated patients. The Per-Protocol population
excludes all patients who violated inclusion or exclusion
criteria of the protocol.
If the 95% confidence interval for the treatment effect
not only lies entirely above -0.1 but also above zero
then there is evidence of superiority in terms of statisti-
cal significance at the 5% level. The difference in pro-
portions between the two treatment arms (Treatment
Arm 1 versus Treatment Arm 2) will be tested with a
Fisher’s exact test to reject the null hypothesis of no
difference.
Secondary Variables
The proportion of patients with haemostasis 5 minutes
and 10 minutes after application will be reported
descriptively based on intent-to-treat population as well
as the per-protocol population. This will include the
proportions, the estimated difference in proportions and
the associated 95% confidence intervals. Differences in
time to haemostasis will be tested with a log-rank test at
the 5% alpha level. Kaplan Meier curves will be dis-
played, with median estimates and confidence limits
provided. The analyses will be based on the intent-to-
treat population and repeated for the per-protocol
population.
Trial organization
The trial is initiated and sponsored by B. Braun Aescu-
lap. The sponsors role during study conduct is limited
to the project co-ordination. An external Clinical
Research Organisation (Centrial GmbH, Tübingen,
Germany) is engaged for monitoring, biometry, and data
management.
Patients will be recruited by seven German and one
Austrian hospitals. Sites are selected according their
experience in liver surgery and their willingness to
adhere to the study protocol. The participating centres
are listed at the end of this paper.
The trial is performed according to the Declaration of
Helsinki in its current German version, the national
laws for medical devices and for drugs, and the guide-
lines for Good Clinical Practice (GCP), as applicable.
The study was approved by the ethics committee of the
Johann Wolfgang Goethe-University, Department of
Medicine, Frankfurt, Germay; approval number 197/09.
Data management and quality assurance
Data is entered in prepared Clinical Report Forms
(CRF). Completed CRF pages are checked by the
responsible monitor with respect to completeness and
plausibility. The data will be transferred into an electro-
nic data processing system by the CRO (CenTrial
GmbH). A double data entry will be performed with a
double data check. During the recruitment phase the
centres will be monitored according to GCP guidelines
by qualified monitors from the CRO.
Ethical aspects
The study was approved by the Ethics Committee of the
University of Frankfurt. Secondary approvals will be
obtained from all ethics committees responsible for the
participating centres. Written informed consent will be
obtained from all study subjects before enrolment into
the study.
Current status and duration of the trial
The study protocol has been completed in January 2009.
A first investigator meeting was held in April, 2008,
where the key points of the study design were discussed
and agreed on by all clinical trial centres. Patient
recruitment started in January, 2010 and is planned to
require 12 months. At the time of submission recruit-
ment is active in six of the eight participating centres.
Discussion
Postoperative bleeding and biliary leakage are - despite
advancement in resection technique - major determi-
nants of morbidity after liver resection, encountered in
4% to 7% of patients [8]. Topical haemostats, glues and
sealants are used regularly in liver surgery trying to pre-
vent complications resulting from haemorrhage. The
ideal haemostat should be efficient in achieving fast and
durable haemostasis and not causing any adverse affects.
Additionally, it should be easy to use and cost efficient.
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new collagen based haemostyptic agent (Sangustop®) is
not inferior to another product with a proven efficacy
(Tachosil®). A non-inferiority study design seems to be
appropriate, since there is good evidence from con-
trolled trials that the active control is efficacious. The
expected margins of a possible difference are so small -
in the range of seconds or few minutes regarding time
to haemostasis - that the clinical relevance of a superior-
ity would be at least questionable. In case Sangustop®
proves to be no worse than Tachosil®, other criteria like
incompatibility with the use of human blood compo-
nents or cost-effectiveness could be taken into considera-
tion. With haemostats potentially being used in all
surgical procedures and with the relatively high costs of
fibrin sealants and similar products, the cost-effectiveness
is of a high importance. The results of this study could
influence the choice of haemostatic therapy in a great
many cases, especially with extensive parenchymatic
bleeding, such as in hepatic resections.
Purified, microfibrillar collagen products have been
introduced as haemostats in the 1970ies and have
become valuable surgical adjunctives. They induce blood
clotting very fast, have a strong adherence to the surface
with low tissue reaction and fast resorption [9]. Preclini-
cal data on the new collagen product Sangustop®
showed very good haemostatic activity. In a pig liver
resection model time to haemostasis was shorter than
for Tachosil® or for oxidized cellulose [6].
Some evidence from randomized controlled trials
(RCT) exists regarding the use of fibrin sealants on their
own or combined with a carrier material [2]. The effi-
cacy of Tachosil® which consists of a collagen fleece car-
rying the fibrin glue components human fibrinogen and
human thrombin has been shown in many clinical stu-
dies in various indications and can be seen as a standard
treatment superior to other locally applicable agents
[4,5]. It was shown in a randomised controlled trial to
be superior in obtaining intra-operative haemostasis
over argon beamer in liver resection [4,10]. The study
by Frilling et al. will serve as the reference for this study
design and conduct. Participants, interventions and out-
come measures are chosen to be similar or equivalent.
Three study centres of the ESSCALIVER - Study (Graz,
Heidelberg, München Grosshadern) participated in the
reference study, too.
Patients undergoing elective hepatic resection are gen-
erally eligible for the study. Liver surgery is to be per-
formed according to accepted surgical standards. For
primary surgical haemostasis only sutures and clips are
allowed.
The efficacy parameter is “time to haemostasis” which
is assessed every minute as presence or absence of hae-
mostasis. Different from the reference study the primary
outcome measure is the proportion of patients who
achieved haemostasis at 3 minutes. The reference study
for Tachosil® as well as the pre-clinical data for Sangu-
stop® suggest that at 3 minutes in the majority of cases
(>70%) haemostasis will be achieved already. Thus the
interesting “time to haemostasis” is the time between 1
and 3 minutes. However, the instructions for use for
Tachosil® require to press the device for at least 3 min-
utes to the wound surface, preventing a measurement
before that time. Therefore, the proportion of patients
with haemostasis after 3 minutes was chosen as the
appropriate primary outcome. Patient proportions at
other time points and the time to haemostasis (Kaplan
Meier curves) will be assessed as secondary parameters.
A limitation of the study is that due to the nature of
the products a blinding of the observer is not possible.
Additionally, the assessment of the time to haemostasis
is subjective and prone to bias. However, there is no
better method available. This is reflected by the fact that
it is the method of choice in comparable studies
[2-6,10].”
The margins of non-inferiority are a crucial decision
in a non-inferiority trial [11]. The basis for the margin
definition in this study were: the reference study, the
preclinical data, and expert opinions. Preclinical data
suggest that Sangustop® is more efficient in achieving
haemostasis than Tachosil®. The reference study shows
that at 3 minutes in ~70% of patients haemostasis was
achieved in contrast to ~50% (difference of ~20%) with
the comparator Argon Laser (figures are estimates
from the published graphs). In the present study the
margins for non-inferiority are set to 10% which firstly
is much smaller than the effect of Tachosil® found in
the reference study, and secondly was decided by the
experts in a study meeting with all participating
centres.
Since the comparator is a pharmaceutical product the
study has to be conducted under the strict regulations
of the national drug law. On the other hand it will addi-
tionally assure a high quality study conduct which is a
criterion for the acceptance of a non-inferiority study
results [11].
Diffuse bleeding from resection surfaces of par-
enchymatous organs remain a challenge in visceral
surgery. Pre-clinical data suggest that Sangustop®
might be a very efficient haemostat, however, without
any pharmaceutically active plasma components. The
present study aims to assess if Sangustop® is non-
inferior to the “gold-standard” product Tachosil®. In
case Sangustop® proves to be as efficient as Tachosil®,
this will allow surgeons to look at additional criteria
like handling characteristics or the cost-effectiveness
for the selection of the most appropriate treatment
for hemostasis.
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